SR
SRPT.O
—
NASDAQ
Biotechnology
Srpt.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-37,5 %
ROE
-62,5 %
Net margin
-38,3 %
Debt / equity
0,73
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$15,56
Open
$15,50
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Sarepta Therapeutics Inc (SRPT.O) operates in the biotechnology sector within the Health Care industry, generating revenue primarily through the commercialization of therapeutic products and collaborations, including a significant exclusive license agreement with Arrowhead Pharmaceuticals.
Business. Sarepta Therapeutics Inc (SRPT.O) operates in the biotechnology sector within the Health Care industry, generating revenue primarily through the commercialization of therapeutic products and collaborations, including a significant exclusive license agreement with Arrowhead Pharmaceuticals.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
JPMorgan Private Bank (United States)
largest disclosed fund holder
Profitability→
-62,5 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,7 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,4 %−2,7 %−0,9 %
Real Estate−0,7 %+10,9 %−1,3 %
Consumer Staples−0,7 %+2,3 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to SRPT.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressJosh Gottheimer — Sarepta Therapeutics, Inc.2023-07-14 · Democrat · NJ · Purchase · $1,001 - $15,000
- CongressJosh Gottheimer — Sarepta Therapeutics, Inc.2023-06-13 · Democrat · NJ · Sale · $1,001 - $15,000
- CongressJosh Gottheimer — Sarepta Therapeutics, Inc.2023-03-06 · Democrat · NJ · Purchase · $1,001 - $15,000
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Sarepta Therapeutics Inc (SRPT.O) operates in the biotechnology sector within the Health Care industry, generating revenue primarily through the commercialization of therapeutic products and collaborations, including a significant exclusive license agreement with Arrowhead Pharmaceuticals.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATEDSarepta Therapeutics maintains a capital structure characterized by significant leverage relative to its equity base, with a debt-to-equity ratio of 0.73. The company holds $801.3 million in cash and equivalents against $829.0 million in long-term debt, resulting in a negative net cash position. Total assets stand at $3.35 billion, while total liabilities amount to $2.21 billion, leaving total equity at $1.14 billion. Liquidity risk is assessed as medium, reflecting the tight balance between cash reserves and debt obligations.
Profitability remains negative, with the company reporting an operating income of -$700.0 million and a net income of -$713.4 million for the latest period. Return on equity is -62.6%, and return on assets is -21.3%, indicating that the company is currently destroying shareholder value through its operations. Operating cash flow is negative at -$205.5 million, further exacerbated by capital expenditures of $102.0 million. These metrics suggest that the company is in a growth or development phase where cash burn exceeds revenue generation.
Revenue concentration and segment details are not explicitly broken down in the provided financial snapshot, but the company generated $1.86 billion in total revenue. The business model relies heavily on strategic partnerships, evidenced by the exclusive license and collaboration agreement with Arrowhead Pharmaceuticals. Geographic exposure and specific segment revenue mixes are not detailed in the available data, limiting the ability to assess concentration risk from these sources.
Growth trajectory analysis is constrained by the absence of historical period data in the input. However, the current revenue level of $1.86 billion suggests a scale of operations typical for a commercial-stage biotechnology firm. Without multi-year historical data, it is not possible to determine the year-over-year growth rate or the sustainability of the current revenue base.
Key risk factors include medium liquidity risk and low dilution risk. The primary financial flag is the negative net cash position after subtracting total debt, which limits financial flexibility. The company’s reliance on external financing or future cash flow generation to service its $829.0 million long-term debt is a critical monitoring point.
Recent events include the execution of an Exclusive License and Collaboration Agreement with Arrowhead Pharmaceuticals on November 25, 2024. This partnership is a key strategic development for the company’s pipeline or commercial strategy. No other significant news events, filing observations, or transcript observations are present in the provided data.
Key takeaways
- Sarepta Therapeutics reports $1.86 billion in revenue but remains unprofitable with a net loss of $713.4 million.
- The company has a negative net cash position, with $801.3 million in cash against $829.0 million in long-term debt.
- Liquidity risk is rated as medium, while dilution risk is low, with 104.96 million shares outstanding.
- A key strategic partnership with Arrowhead Pharmaceuticals was established in November 2024.
- Return on equity is -62.6%, reflecting significant operational losses relative to the equity base.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$15,80
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$1.14B
Net cashⓘ
-$27.7M
Current ratioⓘ
—
Debt / equityⓘ
0.7
ROAⓘ
-21.3%
ROEⓘ
-62.5%
Cash conversionⓘ
29.0%
CapEx / revenueⓘ
5.5%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships8 disclosed relationships · 2 types · extracted from filings & disclosures
Partners1
Arrowhead Pharmaceuticals InARWR.OPartner98%Source ↗
Subsidiaries7
EX21:0abd5edcfdbfEX21:0abd5edcfdbfSubsidiarie97%
EX21:0bbbbe2cfbc7EX21:0bbbbe2cfbc7Subsidiarie97%
EX21:38a856d29fccEX21:38a856d29fccSubsidiarie97%
EX21:56af4bde70a4EX21:56af4bde70a4Subsidiarie97%
EX21:901daabe5055EX21:901daabe5055Subsidiarie97%
EX21:cd9ade2a397aEX21:cd9ade2a397aSubsidiarie97%
EX21:cda635d090f0EX21:cda635d090f0Subsidiarie97%
Supply chain
Vendors → SRPT ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 3,76 |
| Revenue | —no estimate | —no estimate | 1,8B USD |
| Operating income | —no estimate | —no estimate | 471,9M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Corporate eventM&A horizon
M&A probabilityconf 5 %
Probability
5 %
Base rate
3 %
Band
—
180-day horizon · target 2027-01-23 · 1,8× base rate
No acquirer candidates identified by the signal model.
Probabilistic model output — not investment advice. · generated 2026-07-27
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution27 analysts
Strong buy6
Buy3
Hold12
Sell5
Strong sell1
12-month price target$22,59 · Median $20,00
Low $5,00High $38,00
Operating income · consensus471,9M USD
EPS surprise
−289,5 %
reported vs consensus · miss
Revenue surprise
+19,8 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$5,00
Mean$22,59
Median$20,00
High$38,00
Spot$15,80
+43.0 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-37,5 %Above median
Net Margin-38,3 %Above median
ROE-62,5 %Below median
Capex / Rev5,5 %Above median
D/E0,73Bottom quartile
Cash Conv0,29Bottom quartile
Corporate actions / M&A
M&A probabilityconf —
Probability
5 %
Base rate
3 %
Band
Moderate
180-day horizon · target 2027-01-23 · 1,8× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 2 193 892 sh5 exercises · 3 grants4 insiders
- Director, Chief Executive Officer · Stock Options (right to buy) → Common StockAcquired 2 224 342 @ $17,74grant · 2026-07-28
- President, R&D and Tech Ops · Performance Stock Units → Common StockDisposed 8 125exercise · 2026-03-01
- Chief Operating Officer · Performance Stock Units → Common StockDisposed 8 125exercise · 2026-03-01
- Chief Operating Officer · Stock Option (right to buy) → Common StockDisposed 2 069 @ $13,71exercise · 2026-02-26
- Chief Operating Officer · Stock Option (right to buy) → Common StockDisposed 5 381 @ $13,71exercise · 2026-02-26
- President, R&D and Tech Ops · Performance Stock Units → Common StockAcquired 1 875grant · 2026-02-25
- Chief Operating Officer · Performance Stock Units → Common StockAcquired 1 875grant · 2026-02-25
- Director · Stock Option (right to buy) → Common StockDisposed 10 500 @ $13,71exercise · 2026-01-29
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
Source documents
- Sarepta Therapeutics, Inc. Market data — financials · 2026-08-01
- reconciler_enqueue (reconciler) on SRPT.O · 2026-08-01
- SRPT.O HA canonical relationships · 2026-08-01
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-313,47 %$55M
- Investment Managers · as of 2026-03-310,06 %$90M
- Investment Managers · as of 2026-03-310,06 %$139M
- Investment Managers · as of 2024-12-310,02 %$64M
- Investment Managers · as of 2026-03-310,02 %$0M
- Investment Managers · as of 2026-03-310,01 %$11M
- Investment Managers · as of 2026-03-310,00 %$144M
- Institutional Investor · as of 2022-09-300,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$254M
- Investment Managers · as of 2026-03-310,00 %$23M
- Institutional Investor · as of 2026-03-310,00 %$15M
- Investment Managers · as of 2026-03-310,00 %$43M
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$16M
- Investment Managers · as of 2026-03-310,00 %$7M
- Funds · as of 2026-03-310,00 %$9M
- Institutional Investor · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2024-06-300,00 %$48M
- Investment Managers · as of 2026-03-310,00 %$2M
- Brokerage Firms · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Doug S. IngramPresident, Chief Executive Officer, Director
Insider activity
Net selling0 buys · 1 sellsnet -$123K13 insiders · last 365d
- Director, Chief Executive Officer · Common StockOther 756 104 · 2026-07-28
- Director · Common StockOther 16 875 · 2026-06-04
- Director · Common StockOther 16 875 · 2026-06-04
- Director · Common StockOther 16 875 · 2026-06-04
- Director · Common StockOther 16 875 · 2026-06-04
- Director · Common StockOther 16 875 · 2026-06-04
- Director · Common StockOther 16 875 · 2026-06-04
- Director · Common StockOther 16 875 · 2026-06-04
- Director · Common StockOther 16 875 · 2026-06-04
- Director · Common StockSold 7 239 @ $17,02$123K · 2026-03-12
- President, R&D and Tech Ops · Common StockOther 948 @ $17,03$16K · 2026-03-11
- Chief Operating Officer · Common StockOther 1 097 @ $17,03$19K · 2026-03-11
- Chief Financial Officer · Common StockOther 256 @ $17,03$4K · 2026-03-11
- EVP, General Counsel · Common StockOther 974 @ $17,03$17K · 2026-03-11
- Chief Financial Officer · Common StockOther 162 @ $16,95$3K · 2026-03-09
- Chief Financial Officer · Common StockOther 113 @ $16,95$2K · 2026-03-09
- EVP, General Counsel · Common StockOther 484 @ $16,95$8K · 2026-03-09
- EVP, General Counsel · Common StockOther 346 @ $16,95$6K · 2026-03-09
- President, R&D and Tech Ops · Common StockOther 504 @ $16,95$9K · 2026-03-09
- President, R&D and Tech Ops · Common StockOther 895 @ $16,95$15K · 2026-03-09
- Chief Operating Officer · Common StockOther 1 036 @ $16,95$18K · 2026-03-09
- Chief Operating Officer · Common StockOther 583 @ $16,95$10K · 2026-03-09
- President, R&D and Tech Ops · Common StockOther 767 @ $16,20$12K · 2026-03-02
- EVP, General Counsel · Common StockOther 408 @ $16,20$7K · 2026-03-02
- Chief Financial Officer · Common StockOther 450 @ $16,20$7K · 2026-03-02
Short positioning
28.5Mshares short-0.9% vs prior
9.22days to cover
56.4%short of daily vol
38.3Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
SRPT.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorPartnersSubsidiaries
Evidence & claims
From filings & derived data- Pre-tax income (annual): USD -702.23MUnknown
- Operating income (annual): USD -699.78MUnknown
- Cost of revenue (annual): USD 25.5MUnknown
- Net income (annual): USD -713.41MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -7Unknown
- EPS (basic) (annual): USD-PER-SHARES -7Unknown
- Operating cash flow (annual): USD -205.48MUnknown
- Total assets (annual): USD 3.35BUnknown
- Capex (annual): USD 101.97MUnknown
- Cash & equivalents (annual): USD 801.28MUnknown
- Shares outstanding (annual): 104.96MUnknown
- Long-term debt (annual): USD 828.97MUnknown
- Interest expense (annual): USD -38.14MUnknown
- Current assets (annual): USD 2.54BUnknown
- Current liabilities (annual): USD 1.1BUnknown
- Revenue (annual): USD 2.2BUnknown
- Shareholders' equity (annual): USD 1.14BUnknown
- Total liabilities (annual): USD 2.21BUnknown
- Shareholders' equity (annual): USD 1.53BUnknown
- Current assets (annual): USD 3.07BUnknown
- EPS (basic) (annual): USD-PER-SHARES 2Unknown
- Interest expense (annual): USD -18.39MUnknown
- Operating cash flow (annual): USD -205.79MUnknown
- Total liabilities (annual): USD 2.44BUnknown
Showing 24 of 35 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-28INSIDERSEVERINO MICHAEL transacted 756.1k sh — Director, Chief Executive Officer
2026-07-28INSIDERSEVERINO MICHAEL acquired 2.22M sh Stock Options (right to buy) — Director, Chief Executive Officer
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-28 03:14 UTCHOLDERInstitutional holding changed
2026-06-28 03:14 UTCHOLDERInstitutional holding changed
2026-06-28 03:14 UTCHOLDERInstitutional holding changed
2026-06-28 03:14 UTCHOLDERInstitutional holding changed
2026-06-28 03:14 UTCHOLDER4 institutional position changes flagged
2026-06-04 00:00 UTCINSIDER8 insider transactions — 2026-06
2026-06-04 00:00 UTCINSIDER8 insider transactions — 2026-06
2026-06-04INSIDERMayo Stephen transacted 16.9k sh — Director
2026-06-04INSIDERBoor Kathryn Jean transacted 16.9k sh — Director
2026-06-04INSIDERWigzell Hans Lennart Rudolf transacted 16.9k sh — Director
2026-06-04INSIDERBEHRENS M KATHLEEN transacted 16.9k sh — Director
2026-06-04INSIDERConnelly Deirdre P transacted 16.9k sh — Director
2026-06-04INSIDERNicaise Claude transacted 16.9k sh — Director
2026-06-04INSIDERChambers Michael Andrew transacted 16.9k sh — Director
2026-06-04INSIDERBarry Richard transacted 16.9k sh — Director
2026-03-12 00:00 UTCINSIDER23 insider transactions — 2026-03 · net sell $403k 2 derivative
2026-03-12 00:00 UTCINSIDER23 insider transactions — 2026-03 · net sell $403k 2 derivative
2026-03-12INSIDERMayo Stephen sold 7.2k sh — Director ~$123k
2026-03-11INSIDERRodino-Klapac Louise transacted 948 sh — President, R&D and Tech Ops ~$16k
2026-03-11INSIDEREstepan Ian Michael transacted 1.1k sh — Chief Operating Officer ~$19k
2026-03-11INSIDERWong Ryan Ho-Yan transacted 256 sh — Chief Financial Officer ~$4k
2026-03-11INSIDERRothfuss Cristin transacted 974 sh — EVP, General Counsel ~$17k
2026-03-09INSIDERWong Ryan Ho-Yan transacted 162 sh — Chief Financial Officer ~$3k
2026-03-09INSIDERWong Ryan Ho-Yan transacted 113 sh — Chief Financial Officer ~$2k
2026-03-09INSIDERRothfuss Cristin transacted 484 sh — EVP, General Counsel ~$8k
2026-03-09INSIDERRothfuss Cristin transacted 346 sh — EVP, General Counsel ~$6k
2026-03-09INSIDERRodino-Klapac Louise transacted 504 sh — President, R&D and Tech Ops ~$9k
2026-03-09INSIDERRodino-Klapac Louise transacted 895 sh — President, R&D and Tech Ops ~$15k
2026-03-09INSIDEREstepan Ian Michael transacted 1.0k sh — Chief Operating Officer ~$18k
2026-03-09INSIDEREstepan Ian Michael transacted 583 sh — Chief Operating Officer ~$10k
2026-03-02INSIDERRodino-Klapac Louise transacted 767 sh — President, R&D and Tech Ops ~$12k
Showing the 40 most recent of 63 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage